Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Bicycle Therapeutics' Depreciation & Amortization (CF) fell 1915.29% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 468.84%. This contributed to the annual value of $7.2 million for FY2024, which is 959.36% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Depreciation & Amortization (CF) is $1.8 million, which was down 1915.29% from $1.7 million recorded in Q2 2025.
  • Bicycle Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $2.2 million during Q3 2024, with a 5-year trough of $325000.0 in Q1 2021.
  • For the 5-year period, Bicycle Therapeutics' Depreciation & Amortization (CF) averaged around $1.3 million, with its median value being $1.6 million (2025).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 27507.42% in 2022, then plummeted by 1915.29% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $407000.0 in 2021, then skyrocketed by 240.54% to $1.4 million in 2022, then increased by 19.34% to $1.7 million in 2023, then rose by 3.02% to $1.7 million in 2024, then rose by 3.05% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.